Biote (BTMD) Cash & Equivalents (2020 - 2026)

Biote (BTMD) has reported Cash & Equivalents for 7 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 87.24% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (down 87.24% YoY), while the FY2025 annual figure was $24.1 million, down 38.68% from the prior year.
• Cash & Equivalents came in at $5.3 million for Q1 2026 at Biote, down from $24.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $89.0 million in Q4 2023, with the low at $5.3 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $51.7 million, with a median of $41.7 million recorded in 2025.
• Across the five-year window, Cash & Equivalents surged 265.57% in 2022 and slumped 87.24% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $79.2 million in 2022, then climbed by 12.33% to $89.0 million in 2023, then slumped by 55.8% to $39.3 million in 2024, then sank by 38.68% to $24.1 million in 2025, then tumbled by 77.95% to $5.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $5.3 million, $24.1 million, and $28.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.